Wallace Noel R.

Colgate CEO Wallace sells 45,568 shares at $93.91; stock rallied 22.5% in 30 days post-filing

Wallace Noel R., as Chairman, President & CEO, sold 45,568 shares of Colgate Palmolive at $93.91, reducing his holdings by 13.5% to 293,188 shares. The sale occurred when the stock was trading 3.2% below its 52-week high and has since appreciated $0.50 per share. Across his prior sales at Colgate, the insider's timing has been mixed—only 1 of 5 prior sales at this ticker were well-timed at the 90-day mark, with his most recent sale on 2024-11-22 followed by a 7.5% decline versus typical gains of 5.2%–14.4% on his February 2024 sales. His cross-ticker track record shows a 28.57% well-timed rate on 7 prior sales with an average 90-day return of +6.1%, suggesting modest but inconsistent selling acuity. The company's fundamentals remain stable with a P/E of 26.15 and modest 3.3% annual revenue growth, offering limited insight into executive conviction.

Wallace Noel R. (CEO) sells 33,333 shares of Colgate-Palmolive at $95.00; 11.0% reduction in holdings post-transaction.

Wallace Noel R., Chairman, President & CEO, sold 33,333 shares of CL at $95.00 on 2024-11-22, reducing his holdings from 304,022 shares to 270,689 shares. The sale occurred 11.2% below the 52-week high of $108.77 and at a price 1.6% below the current price of $96.58. Notably, his prior trades at Colgate-Palmolive show poor 90-day timing patterns: all 5 prior sales at this ticker yielded positive 90-day returns (ranging from +5.2% to +14.4%), indicating the stock rose after each sale—the opposite of well-timed selling. This sale follows the same pattern, with the stock currently trading higher than his transaction price, suggesting no protective signal is present. With a P/E of 27.52 and strong fundamentals (annual revenue growth of +8.3%, latest quarterly revenue of $5.0B, and net income of $737.0M), the company remains financially sound, limiting interpretive scope to transaction mechanics rather than company health concerns.